news
Researchers reveal structure of SARS-CoV-2 Envelope protein
The molecular structure of the SARS-CoV-2 Envelope protein has been identified by researchers using nuclear magnetic resonance.
List view / Grid view
Proteomics
article
Developing nanobodies and sybodies to combat COVID-19
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
news
Furin cleavage motif makes SARS-CoV-2 more aggressive than other CoVs, find scientists
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
news
Novel nanoparticle therapy shows promise in glioblastoma
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
news
Researchers develop ACE2 decoy to neutralise SARS-CoV-2
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
news
Pre-existing coronavirus antibodies could protect against new COVID-19 strains
Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.
news
Developing drugs for disordered proteins
Scientists have developed a drug-like molecule to target amyloid-beta, a disordered protein implicated in Alzheimer's disease that has been considered undruggable.
news
D614G mutation may make SARS-CoV-2 more contagious
According to a new study, the SARS-CoV-2 virus is accumulating genetic mutations, including one called D614G which may have made it more contagious.
news
SARS-CoV-2 can disrupt the blood-brain barrier, find scientists
Binding of SARS-CoV-2 spike proteins to the brain’s endothelial cells can cause the blood-brain barrier to become leaky, potentially causing the neurological symptoms associated with COVID-19.
news
SARS-CoV-2 specific antibodies persist for five months in mild cases
In a study of mild-to-moderate COVID-19 patients scientists established that the level of certain antibodies remained stable for five months.
news
Cellular senescence as a drug target
New research reveals that age-related declines in cellular function and proliferation occur in multiple stages, accompanied by different inflammatory responses.
![A coiling protein 'shell,' called a nucleocapsid, shown here, surrounds Ebola's genetic material, which consists of single-strand RNA. University of Delaware researchers are simulating the way molecules of this nucleocapsid move and interact, atom by atom, to understand their functions and expose targets for anti-viral treatments [Credit: Juan Perilla Laboratory].](https://drug.russellpublishing.co.uk/wp-content/uploads/Ebola-nucleocapsid-e1603365997854.jpg)
news
The nucleocapsid as a novel drug target for Ebola virus
Using supercomputer stimulations researchers reveal that the structural stability of the Ebola nucleocapsid is depended on the presence of RNA and interactions with charged ions.
news
Severe COVID-19 symptoms may not be caused by cytokine storm
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
news
Novel Alzheimer’s vaccine shows promise in murine models
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
news
First draft sequence of human proteome released
Researchers have mapped 90 percent of the human proteome, which could inform the development of new medicines.
